Therapeutic and prophylactic thalidomide in TNBS-induced colitis: synergistic effects on TNF-alpha, IL-12 and VEGF production (Q34098863)

31 July 2017

title

Therapeutic and prophylactic thalidomide in TNBS-induced colitis: synergistic effects on TNF-alpha, IL-12 and VEGF production (English)

1 reference

31 July 2017

0 references

0 references

1 reference

Ana Teresa Carvalho

1

1 reference

31 July 2017

Heitor Souza

2

1 reference

31 July 2017

Antonio Jose Carneiro

3

1 reference

31 July 2017

Morgana Castelo-Branco

4

1 reference

31 July 2017

Kalil Madi

5

1 reference

31 July 2017

Alberto Schanaider

6

1 reference

31 July 2017

Flavia Silv

7

1 reference

31 July 2017

Fernando Antonio Pereira Junior

8

1 reference

31 July 2017

Marcia G Pereira

9

1 reference

31 July 2017

Claudio Tortori

10

1 reference

31 July 2017

Ilana Dines

11

1 reference

31 July 2017

Jane Carvalho

12

1 reference

31 July 2017

Eduardo Rocha

13

1 reference

31 July 2017

Celeste Elia

14

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 April 2007

1 reference

World Journal of Gastroenterology

31 July 2017

published in

1 reference

31 July 2017

volume

13

1 reference

31 July 2017

issue

15

1 reference

31 July 2017

page(s)

2166-2173

1 reference

Thalidomide treatment reduces colon injury induced by experimental colitis

31 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4146838

Anti-interleukin-12 antibody for active Crohn's disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4146838

Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4146838

Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4146838

TNF-alpha neutralization ameliorates the severity of murine Crohn's-like ileitis by abrogation of intestinal epithelial cell apoptosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4146838

Inflammatory Bowel Disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4146838

Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4146838

Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4146838

Thalidomide impairment of trinitrobenzene sulphonic acid-induced colitis in the rat - role of endothelial cell-leukocyte interaction

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4146838

Loss of transforming growth factor beta signalling in the intestine contributes to tissue injury in inflammatory bowel disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4146838

The role of chemokines and chemokine receptors in mucosal inflammation.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4146838

Up-regulation of the IL-12 receptor beta 2 chain in Crohn's disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4146838

Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4146838

An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4146838

Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4146838

Inflammatory bowel disease: Etiology and pathogenesis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4146838

Increased Serum Levels of Vascular Endothelial Growth Factor in Patients with Inflammatory Bowel Disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4146838

Molecular analysis of blood vessel formation and disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4146838

In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4146838

Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4146838

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4146838

Antibodies to interleukin 12 abrogate established experimental colitis in mice

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4146838

Treatment of refractory rheumatoid arthritis--the thalidomide experience

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4146838

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4146838

Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4146838

Infliximab downregulates basic fibroblast growth factor and vascular endothelial growth factor in Crohn's disease patients.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4146838

A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4146838

Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4146838

Vascular permeability factor/vascular endothelial cell growth factor-mediated permeability occurs through disorganization of endothelial junctional proteins.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4146838

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4146838

Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4146838

Doppler US in patients with crohn disease: vessel density in the diseased bowel reflects disease activity

28 October 2018

1 reference

12 December 2020

VEGF, basic-FGF, and TGF-beta in Crohn's disease and ulcerative colitis: a novel mechanism of chronic intestinal inflammation

1 reference

12 December 2020

Transmembrane TNF-alpha, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn's disease

1 reference

12 December 2020

Therapeutic effect of anti-OX40L and anti-TNF-alpha MAbs in a murine model of chronic colitis

1 reference

12 December 2020

Hapten-induced model of chronic inflammation and ulceration in the rat colon

1 reference

12 December 2020

Tumour necrosis factor alpha in stool as a marker of intestinal inflammation

1 reference

12 December 2020

Thalidomide for the treatment of chronic graft-versus-host disease

1 reference

12 December 2020

Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease

1 reference

12 December 2020

Chronic cutaneous lupus erythematosus treated with thalidomide

1 reference

12 December 2020

Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells

1 reference

12 December 2020

Inhibition of IL-12 production by thalidomide

1 reference

12 December 2020

Tumour necrosis factor α and interleukin 1β in relapse of Crohn's disease

1 reference

12 December 2020

Elevated serum vascular endothelial growth factor in children and young adults with Crohn's disease

1 reference

12 December 2020

Increased production of vascular endothelial growth factor by intestinal mucosa of patients with inflammatory bowel disease

1 reference

12 December 2020

Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha

1 reference

12 December 2020

VEGF-A stimulation of leukocyte adhesion to colonic microvascular endothelium: implications for inflammatory bowel disease

1 reference

12 December 2020

Identifiers

DOI

10.3748/WJG.V13.I15.2166

1 reference

31 July 2017

1 reference

31 July 2017

1 reference